conferenceseries.com

Global Summit on VACCINES AND IMMUNOLOGY

April 19, 2022 | Webinar

Healing of severe Herpes Zoster Ophthalmicus within few days by combination of acyclovir and an attenuated dsRNA viral vaccine.

Tibor Bakacs
HepC Inc, Hungary

Statement of the Problem: Herpes zoster ophthalmicus with severe orbital edema is an ophthalmologic emergency. The 75-year-old author felt an intermittent throbbing pain in more than three dermatomes including the frontal, orbital, temporal, and occipital/nuchal areas. Since the prodromal and erythematous phase started with atypical signs, conventional acyclovir treatment was administered belatedly, 96 hours after the first symptoms despite the fact that the efficacy of acyclovir 72 hours after the onset of skin rash has never been confirmed. Conventional treatment was therefore complemented with the experimental antiviral super infection therapy. Methodology & Theoretical Orientation: Superinfection is a host-directed therapy during which the non-pathogenic avian live attenuated infectious bursal disease vaccine virus (IBDV) delivers its double-stranded RNA cargo to host cells. IBDV activates the natural antiviral interferon gene defense system via toll-like receptors from within the ribosomes. Findings: The orally administered attenuated live IBDV vaccine virus (7x106 IU in 4 days) rapidly decreased the orbital edema and most symptoms were resolved within five days (Figure 1. A, B, C, D). Conclusion & Significance: Previously, IBDV had successfully treated hepatitis A virus (HAV) infection in marmoset monkeys, and hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in patients with acute and chronic (decompensated) hepatitis. The proof-of-principle of oral IBDV treatment was recently demonstrated in three patients with COVID-19 disease. Such a way, IBDV was proven to be effective against five different viruses. IBDV is administered in an outpatient setting, it is easy to manufacture and will be affordable even in resource-limited countries. The German Paul Ehrlich Institute supports a phase I safety study for persons acutely infected with SARS CoV-2.

Biography

I am a medical doctor, clinically trained scientist with over 40 years of experience, publisher of more than 80 scientific papers. I addressed unmet medical needs. 1) Curing viral diseases with an attenuated live dsRNA vaccine virus (Home - Superinfection Therapy); the clinically validated viral super infection therapy (SIT) may mitigate symptoms of COVID-19 infections (https://www.preprints.org/manuscript/202002.0147/v4). 2) Exploiting autoimmunity unleashed by an off-label low□ dose immune checkpoint blockade to treat advanced cancer; we demonstrated in 131 unselected stage IV cancer patients that hyperthermia, combined with IL-2 treatment and off-label low doses of ipilimumab (0.3 mg/kg) plus nivolumab (0.5 mg/kg) can be converted from a palliative therapy into a treatment with curative intent because the autoimmune forces unleashed by ICI drugs can be harnessed by a multicomponent T-cell stimulation therapy.